Sanofi (NASDAQ:SNY) Shares Acquired by Farther Finance Advisors LLC

Farther Finance Advisors LLC lifted its holdings in Sanofi (NASDAQ:SNY) by 12.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,861 shares of the company’s stock after purchasing an additional 309 shares during the period. Farther Finance Advisors LLC’s holdings in Sanofi were worth $165,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of SNY. Allspring Global Investments Holdings LLC increased its stake in shares of Sanofi by 773.4% during the first quarter. Allspring Global Investments Holdings LLC now owns 5,651 shares of the company’s stock worth $275,000 after purchasing an additional 5,004 shares in the last quarter. SG Americas Securities LLC raised its holdings in shares of Sanofi by 3.0% during the first quarter. SG Americas Securities LLC now owns 15,690 shares of the company’s stock valued at $763,000 after acquiring an additional 456 shares during the last quarter. Atomi Financial Group Inc. lifted its position in shares of Sanofi by 19.1% in the first quarter. Atomi Financial Group Inc. now owns 10,995 shares of the company’s stock valued at $534,000 after acquiring an additional 1,761 shares in the last quarter. Sei Investments Co. boosted its stake in shares of Sanofi by 9.3% in the first quarter. Sei Investments Co. now owns 554,028 shares of the company’s stock worth $26,926,000 after acquiring an additional 47,297 shares during the last quarter. Finally, QRG Capital Management Inc. increased its position in shares of Sanofi by 9.7% during the first quarter. QRG Capital Management Inc. now owns 134,520 shares of the company’s stock worth $6,538,000 after purchasing an additional 11,902 shares in the last quarter. Institutional investors and hedge funds own 10.04% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on SNY. StockNews.com lowered Sanofi from a “strong-buy” rating to a “buy” rating in a report on Thursday. Argus upped their price objective on shares of Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Finally, Citigroup raised shares of Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Two research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Sanofi currently has an average rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Price Performance

Shares of SNY opened at $51.32 on Monday. Sanofi has a fifty-two week low of $45.13 and a fifty-two week high of $58.97. The firm’s 50 day moving average price is $55.49 and its 200 day moving average price is $52.24. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. The company has a market cap of $130.24 billion, a P/E ratio of 26.18, a PEG ratio of 1.31 and a beta of 0.61.

Sanofi (NASDAQ:SNY) last issued its earnings results on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, beating the consensus estimate of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The firm had revenue of $13.44 billion for the quarter, compared to analysts’ expectations of $16.59 billion. During the same quarter last year, the company earned $2.55 earnings per share. The firm’s revenue was up 12.3% compared to the same quarter last year. On average, research analysts forecast that Sanofi will post 4.27 earnings per share for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.